50 likes | 136 Views
This study evaluates the efficacy of high-dose versus standard-dose clopidogrel in patients with high on-treatment platelet reactivity after PCI. The multicenter randomized trial focused on patients with PCI using 1 or more DES for stable CAD or non-STEMI. The primary endpoint was MACE at 6 months, including cardiac death, MI, and stent thrombosis. Safety was assessed based on severe or moderate bleeding according to the GUSTO definition. The conclusion indicated that high-dose clopidogrel did not significantly reduce the incidence of MACE or bleeding compared to the standard dose in this patient population. (Word count: 86)
E N D
Standard vs High-dose Clopidogrelafter PCI: GRAVITAS Objective: to evaluate high-dose with standard dose clopidogrel in patients with high on-treatmentplateletreactivity (≥230 PRU) after PCI Study: multicenterrandomized double-blind trialPopulation: patients with PCI with 1 or more DES for stable CAD or non-STEMI Endpoint: MACE: cardiacdeath, MI, stentthrombosisat 6 monthsSafety: severe or moderatebleeding (GUSTO definition)
Standard vs High-dose Clopidogrelafter PCI: GRAVITAS Conclusion high-dose clopidogreldoes not reduce incidence of MACE or bleedingcompared to standard dose in patients with high on-treatmentreactivity Price JAMA 2011;305:1097-1105